SCHEMBL23901571

SCHEMBL23901571

Cc1cc(-c2cccnc2)nc2c(C(=O)NC(=O)c3ccc(F)cc3)ncn12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.46
ABL1 P00519 3/20 0.45
BCR P11274 3/20 0.45
PDGFRB P09619 2/20 0.45
PDGFRA P16234 2/20 0.45
DYRK1A Q13627 2/20 0.42
CLK1 P49759 1/20 0.42
ATR Q13535 1/20 0.42
MKNK1 Q9BUB5 1/20 0.41
MKNK2 Q9HBH9 1/20 0.41
HDAC2 Q92769 1/20 0.41
CYP11B1 P15538 2/20 0.41
CYP11B2 P19099 2/20 0.41
GAA P10253 2/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GRM1 Q13255 1/20 0.40
RAB9A P51151 1/20 0.40
F2 P00734 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21479288 0.83 LMNA (0.44) LMNAABL1BCRPDGFRBPDGFRA
SCHEMBL19438221 0.82 CNR2 (0.42) LMNAABL1BCRPDGFRBPDGFRA
SCHEMBL19449609 0.82 DYRK1A (0.47) LMNADYRK1AATRKMT2A
SCHEMBL19681745 0.82 ADORA2A (0.39) LMNAABL1BCRPDGFRBPDGFRA
SCHEMBL19438303 0.80 KDM4E (0.46) LMNAABL1BCRATRMKNK1
SCHEMBL19681732 0.79 MKNK1 (0.44) LMNAATRMKNK1MKNK2KMT2A
SCHEMBL19438386 0.78 KDM4E (0.42) ATRMAPTSMN1; SMN2RAB9A
SCHEMBL19438385 0.78 KDM4E (0.42) ATRMAPTSMN1; SMN2RAB9A
SCHEMBL19449422 0.77 DYRK1A (0.49) DYRK1APOLBMAPTSMN1; SMN2KMT2A
SCHEMBL19438272 0.77 TYRO3 (0.41) DYRK1AATRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210309661-A1 IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL - R&D INVESTMENTS, S.A. (PT) 2021-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210309661-A1 IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, GBA2 LMNA 836/4885ABL1 446/4885BCR 2761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.